Archive: 07/12/2019

E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. The results show that the combination of ibrutinib, ...

Dec 7, 2019

Genomic features of AML in patients over age 60 can predict success of stem cell transplant

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber ...

Dec 7, 2019

0

5

Lymphoma patients may have new path to remission, even when CAR T therapy fails

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission. A global, multi-center ...

Dec 7, 2019

Archive: 07/12/2019

E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients

Genomic features of AML in patients over age 60 can predict success of stem cell transplant

Lymphoma patients may have new path to remission, even when CAR T therapy fails

Women, exercise and longevity

Emerging role of adenosine in brain disorders and amyotrophic lateral sclerosis

Phys.org

Tech Xplore

Science X